Eli Lilly & Co.

The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while the Nasdaq saw a decline of 0.2% to 19,044.39. The S&P 500 showed modest gains. rising 0.1% to 5,842.91. These are the top stocks that gained the attention of retail...

On Thursday, major U.S. indices showed mixed results. The Dow Jones Industrial Average increased by 0.2% to 39,935.07, while the S&P 500 fell by 0.5% to 5,399.22. The Nasdaq dropped 0.9% to 17,181.72. Let’s take a closer look at the top stocks that caught the attention of retail traders...

On Thursday, major U.S. stock indices were down, with the Dow Jones Industrial Average dropping nearly 1.3% to 40,665.03, the S&P 500 falling almost 0.8% to 5,544.59, and the Nasdaq decreasing 0.7% to 17,871.22. Palantir Technologies Inc. (NYSE:PLTR) Palantir’s shares rose by 1.49% to...

On Monday, major U.S. indices closed positively, with the Dow Jones Industrial Average rising by 0.2% to 38,868.04. The S&P 500 increased by 0.3% to 5,360.79, and the Nasdaq climbed by 0.35% to finish at 17,192.53. Apple Inc. (NASDAQ:AAPL) Apple’s stock dipped by 1.91% to close at $193.12...

CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip. What Happened: Cramer, in his show “Mad Money,” dismissed the notion of sector bubbles and encouraged investors to be...

In a recent announcement, Eli Lilly and Co (NYSE:LLY) has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the...

U.S. stocks traded lower at the end of trading on Monday with the Dow Jones Industrial Average declining 0.7% to 38,380.12 and the S&P 500 dropping 0.3% to 4,942.81. The Nasdaq ended Monday lower by 0.2% at 15,597.68. These are the top stocks that gained the attention of retail traders and...

Tesla Inc. (NASDAQ:TSLA) has been surpassed in market value by pharmaceutical giant Eli Lilly (NYSE:LLY), following a 12% single-day plunge in Tesla’s stock. What Happened: Tesla’s fourth-quarter earnings report, which fell short of revenue and profit expectations, triggered a...

U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34. The S&P 500 and Nasdaq fell 0.34% and 0.56% to 4,688.68 and 14,510.30 respectively. These are the top stocks that gained the attention of retail traders and investors throughout the day:...

Eli Lilly and Co. (NYSE:LLY) could witness a 140% surge in its shares, as predicted by Goldman Sachs. The growth is anticipated to be driven by an increased demand for GLP-1 weight loss and diabetes drugs. What Happened: Goldman Sachs’ latest research suggests a bright future for Eli Lilly,...

What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs’ market impact. However, with...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. The Dow traded up 0.4% to 33,739.30 while the NASDAQ rose 0.58% to 13,562.84. The S&P 500 also rose, gaining 0.52% to 4,358.24. These are the top stocks that gained the attention of...

On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel narrowly recommended approval for the company's gene therapy for Duchenne Muscular Dystrophy (DMD)....

Eli Lilly & Co. (NYSE: LLY) planned to go back to the drawing board with its new experimental Alzheimer’s drug, according Bloomberg. The drug, solanezumab, which was not successful with advanced Alzheimer’s patients, will be tested in patients who show signs of early stages of the disease...

It’s a simple matter of math. The more diseases there are to treat, the more profit there is to be made – by drug companies that produce the medicines designed to treat those diseases. The Wall Street Journal reported Wednesday that the 5th edition of the Diagnostic and Statistic Manual of...